Brandon Folkes Analyst Performance

Analyst at HC Wainwright

Brandon Folkes is a stock analyst at HC Wainwright focused in the medical sector, covering 37 publicly traded companies. Over the past year, Brandon Folkes has issued 83 stock ratings, including strong buy and buy recommendations. While full access to Brandon Folkes' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brandon Folkes' coverage history, rating activity, and performance tendencies â€” helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 139 Last 9 Years
Buy Recommendations: 94.93% 131 Buy Ratings
Companies Covered: 37 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.7%	1 ratings
Buy	94.2%	130 ratings
Hold	5.1%	7 ratings
Sell	0.0%	0 ratings

Out of 138 total stock ratings issued by Brandon Folkes at HC Wainwright, the majority (94.2%) have been Buy recommendations, followed by 5.1% Hold and 0.7% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
AXGN
Jun 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
IMV
Sep 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	86.5% of companies on NASDAQ	32 companies
NYSEAMERICAN	5.4% of companies on NYSEAMERICAN	2 companies
NYSE	5.4% of companies on NYSE	2 companies
TSE	2.7% of companies on TSE	1 company

Brandon Folkes, an analyst at HC Wainwright, currently covers 37 companies listed on NASDAQ, NYSEAMERICAN, NYSE and TSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 36 companies	97.3%
	Manufacturing 1 company	2.7%

Brandon Folkes of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 15 companies	40.5%
MED - DRUGS 11 companies	29.7%
MED PRODUCTS 4 companies	10.8%
MED INSTRUMENTS 3 companies	8.1%
BIOTECHNOLOGY 2 companies	5.4%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES 1 company	2.7%
PHARMACEUTICAL PREPARATIONS 1 company	2.7%

About Brandon Folkes

Brandon Folkes has over a decade of experience in biopharma and biotechnology equity research. Prior to joining H.C. Wainwright, he served as Managing Director, Equity Research at Rodman & Renshaw and Managing Director, Equity Research at Cantor Fitzgerald. Prior to his tenure at Cantor, Mr. Folkes held equity research positions at Guggenheim Partners and CRT Capital. Before joining Wall Street, Mr. Folkes occupied roles at KPMG and PwC in the U.S., South Africa, and British Virgin Islands. Mr. Folkes holds degrees from Stellenbosch University and The University of South Africa; and earned the CFA and Chartered Accountancy designations.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
SINT Sintx Technologies	5/20/2026	Reiterated Rating	$2.20	$10.00	Buy
TRAW Traws Pharma	5/20/2026	Reiterated Rating	$1.59	$8.00	Buy
OMER Omeros	5/14/2026	Reiterated Rating	$14.38	$40.00	Buy
MNKD MannKind	5/7/2026	Boost Price Target	$3.56	$10.00	Buy
TRVI Trevi Therapeutics	5/6/2026	Reiterated Rating	$14.66	$21.00	Buy
EPRX Eupraxia Pharmaceuticals	5/4/2026	Reiterated Rating	$7.55	$11.00	Buy
EPRX Eupraxia Pharmaceuticals	4/22/2026	Reiterated Rating	$7.02	$11.00	Buy
ACHV Achieve Life Sciences	4/16/2026	Reiterated Rating	$3.55	$12.00	Buy
SINT Sintx Technologies	4/13/2026	Initiated Coverage	$2.68	$10.00	Buy
RANI Rani Therapeutics	3/27/2026	Reiterated Rating	$1.08	$11.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
DERM Journey Medical	3/26/2026	Reiterated Rating	$6.83	$13.00	Buy
ACHV Achieve Life Sciences	3/25/2026	Reiterated Rating	$2.90	$12.00	Buy
COLL Collegium Pharmaceutical	3/20/2026	Reiterated Rating	$36.30	$60.00	Buy
PTHS Pelthos Therapeutics	3/19/2026	Reiterated Rating	$22.44	$60.00	Buy
EPRX Eupraxia Pharmaceuticals	3/17/2026	Lower Price Target	$7.39	$11.00	Buy
SGMT Sagimet Biosciences	3/11/2026	Reiterated Rating	$5.65	$29.00	Buy
TRVI Trevi Therapeutics	3/9/2026	Reiterated Rating	$11.80	$21.00	Buy
XERS Xeris Biopharma	3/2/2026	Reiterated Rating	$6.08	$10.00	Buy
MNKD MannKind	2/25/2026	Reiterated Rating	$3.54	$11.00	Buy
PYPD PolyPid	2/11/2026	Reiterated Rating	$4.59	$13.00	Buy
ENTA Enanta Pharmaceuticals	2/10/2026	Reiterated Rating	$13.83	$20.00	Buy
CRDL Cardiol Therapeutics	2/10/2026	Reiterated Rating	$1.09	$9.00	Buy
SGMT Sagimet Biosciences	2/3/2026	Reiterated Rating	$6.23	$29.00	Buy
MNKD MannKind	1/26/2026	Reiterated Rating	$5.49	$11.00	Buy
CRMD CorMedix	1/23/2026	Lower Price Target	$7.44	$13.00	Buy
INDV Indivior	1/12/2026	Boost Price Target	$35.44	$48.00	Buy
COLL Collegium Pharmaceutical	1/9/2026	Reiterated Rating	$48.78	$60.00	Buy
ENTA Enanta Pharmaceuticals	1/9/2026	Reiterated Rating	$13.44	$20.00	Buy
TRVI Trevi Therapeutics	1/9/2026	Reiterated Rating	$11.21	$21.00	Buy
RANI Rani Therapeutics	1/9/2026	Reiterated Rating	$1.39	$11.00	Buy
EPRX Eupraxia Pharmaceuticals	1/9/2026	Reiterated Rating	$8.59	$12.00	Buy
XERS Xeris Biopharma	1/9/2026	Reiterated Rating	$8.13	$10.00	Buy
HRTX Heron Therapeutics	1/9/2026	Reiterated Rating	$1.50	$6.00	Buy
MNKD MannKind	1/8/2026	Reiterated Rating	$6.16		Buy
OMER Omeros	1/8/2026	Boost Price Target	$14.09	$40.00	Buy
MIST Milestone Pharmaceuticals	1/6/2026	Reiterated Rating	$2.06	$8.00	Buy
ZVRA Zevra Therapeutics	12/30/2025	Set Price Target	$8.82	$26.00
OMER Omeros	12/24/2025	Reiterated Rating	$14.93		Buy
MIST Milestone Pharmaceuticals	12/15/2025	Boost Price Target	$2.55	$8.00	Buy
TRAW Traws Pharma	12/3/2025	Initiated Coverage	$2.16	$8.00	Buy
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad) The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. See the 5 stocks to avoid
TRAW Traws Pharma	12/3/2025	Initiated Coverage	$2.11	$8.00	Buy
CRDL Cardiol Therapeutics	12/1/2025	Reiterated Rating	$0.89	$9.00	Buy
CRMD CorMedix	11/13/2025	Boost Price Target	$11.42	$18.00	Buy
MNKD MannKind	11/10/2025	Reiterated Rating	$5.44		Buy
XERS Xeris Biopharma	11/7/2025	Reiterated Rating	$7.44	$10.00	Buy
COLL Collegium Pharmaceutical	11/7/2025	Boost Price Target	$40.66	$46.00	Buy
INDV Indivior	10/30/2025	Boost Price Target	$29.53	$35.00	Buy
RANI Rani Therapeutics	10/21/2025	Reiterated Rating	$2.25	$11.00	Buy
OMER Omeros	10/15/2025	Boost Price Target	$10.20	$20.00	Buy
MNKD MannKind	10/13/2025	Reiterated Rating	$4.88	$11.00	Buy
GNFT GENFIT	9/24/2025	Lower Price Target	$3.65	$7.00	Buy
RNTX Rein Therapeutics	9/22/2025	Initiated Coverage	$1.21	$10.00	Buy
RNTX Rein Therapeutics	9/22/2025	Initiated Coverage	$1.18	$10.00	Buy
MNKD MannKind	9/18/2025	Reiterated Rating	$5.39	$11.00	Buy
ANIP ANI Pharmaceuticals	9/17/2025	Boost Price Target	$96.81	$121.00	Buy
MNKD MannKind	9/2/2025	Boost Price Target	$5.72	$11.00	Buy
MNKD MannKind	8/25/2025	Reiterated Rating	$4.05	$9.00	Buy
DERM Journey Medical	8/25/2025	Initiated Coverage	$7.47	$13.00	Buy
VALN Valneva	8/25/2025	Reiterated Rating	$9.45	$18.00	Buy
ACHV Achieve Life Sciences	8/21/2025	Initiated Coverage	$2.58	$12.00	Buy
EPRX Eupraxia Pharmaceuticals	8/20/2025	Reiterated Rating	$5.38	$12.00	Buy
GNFT GENFIT	8/19/2025	Initiated Coverage	$4.50	$9.00	Buy
VALN Valneva	8/19/2025	Initiated Coverage	$12.14	$18.00	Buy
PYPD PolyPid	8/13/2025	Reiterated Rating	$3.52	$13.00	Buy
CNTB Connect Biopharma	8/13/2025	Reiterated Rating	$2.29	$7.00	Buy
XERS Xeris Biopharma	8/12/2025	Initiated Coverage	$7.20	$10.00	Buy
COLL Collegium Pharmaceutical	8/11/2025	Upgrade	$34.93	$44.00	Strong-Buy
ANIP ANI Pharmaceuticals	8/8/2025	Reiterated Rating	$81.49	$93.00	Buy
CRMD CorMedix	8/8/2025	Lower Price Target	$10.81	$17.00	Buy
SGMT Sagimet Biosciences	8/7/2025	Upgrade	$9.17	$29.00	Buy
INDV Indivior	8/6/2025	Initiated Coverage	$21.80	$27.00	Buy
ENTA Enanta Pharmaceuticals	7/28/2025	Initiated Coverage	$7.40	$20.00	Buy
MNKD MannKind	7/16/2025	Upgrade	$3.85	$9.00	Buy
ANIP ANI Pharmaceuticals	7/10/2025	Initiated Coverage	$65.31	$84.00	Buy
ZVRA Zevra Therapeutics	7/2/2025	Initiated Coverage	$8.95	$26.00	Buy
CRMD CorMedix	6/30/2025	Initiated Coverage	$12.50	$20.00	Buy
EPRX Eupraxia Pharmaceuticals	6/26/2025	Initiated Coverage	$4.31	$12.00	Buy
CNTB Connect Biopharma	6/12/2025	Initiated Coverage	$0.82	$7.00	Buy
HRTX Heron Therapeutics	6/9/2025	Initiated Coverage	$2.10	$6.00	Buy
MIST Milestone Pharmaceuticals	6/5/2025	Upgrade	$1.65	$5.00	Buy
CRDL Cardiol Therapeutics	6/2/2025	Initiated Coverage	$1.25	$9.00	Buy
PYPD PolyPid	6/2/2025	Upgrade	$2.84	$11.00	Buy
TRVI Trevi Therapeutics	5/28/2025	Initiated Coverage	$6.16	$21.00	Buy

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.